Erratum: PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: Pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab (Annals of Oncology (2016) 27 (1519–1525) DOI: 10.1093/annonc/mdw197);PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: Pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of Oncology

Volumn 27, Issue 8, 2016, Pages 1519-1525

  Loibl, Sibylle ^a   Majewski, I ^b   Guarneri, V ^c   Nekljudova, V ^a   Holmes, E ^d   Bria, E ^e   Denkert, C ^f   Schem, C ^g   Sotiriou, C ^h   Loi, S ⁱ   Untch, M ^j   Conte, P ^c   Bernards, R ^b   Piccart, M ^h   von Minckwitz, G ^a   Baselga, J ^k  

^a German Breast Group   (Germany)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY OF PADOVA   (Italy)

^d FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^e UNIVERSITY OF VERONA   (Italy)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h JULES BORDET INSTITUTE   (Belgium)

ⁱ PETER MACCALLUM CANCER CENTRE   (Australia)

^j Helios Klinikum   (Germany)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Double anti HER2 treatment; HER2+ breast cancer; Neoadjuvant; Pathological complete response; PIK3CA; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADJUVANT THERAPY; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; GENE; GENE INTERACTION; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MONOTHERAPY; MUTANT; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PIK3CA GENE; PRIMARY HER2 POSITIVE BREAST CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST TUMOR; CLINICAL TRIAL (TOPIC); FEMALE; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84985015825     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx803     Document Type: Erratum

References (28)

1. Loibl S. Neoadjuvant treatment of breast cancer: maximizing pathologic complete response rates to improve prognosis. Curr Opin Obstet Gynecol 2015; 27: 85-91.
2. Schneeweiss A, Chia S, Hickish T et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24: 2278-2284.
3. Bachman KE, Argani P, Samuels Y et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3: 772-775.
4. Loibl S, von Minckwitz G, Schneeweiss A et al. PIK3CA mutations are associated with lower rates of pathological complete response (pCR) to anti-HER2 therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014; 32: 3212-3220.
5. Majewski IJ, Nuciforo P, Mittempergher L et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol 2015; 33: 1334-1339.
6. Guarneri V, Dieci MV, Frassoldati A et al. Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2- positive breast cancer. Oncologist 2015; 20: 1001-1010.
7. Hanusch C, Schneeweiss A, Loibl S et al. Dual blockade with afatinib and trastuzumab as neoadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy- DAFNE (GBG-70). Clin Cancer Res 2015; 21: 2924-2931.
8. Untch M, Rezai M, Loibl S et al. Neoadjuvant treatment with trastuzumab in HER2- positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28: 2024-2031.
9. Untch M, Loibl S, Bischoff J et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13: 135-144.
10. von Minckwitz G, Schneeweiss A, Loibl S et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15: 747-756.
11. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab forHER2- positive early breast cancer (NeoALTTO): a randomised, open label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
12. Guarneri V, Frassoldati A, Bottini A et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2- positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012; 30: 1989-1995.
13. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-1184.
14. Guarneri V, Generali DG, Frassoldati A et al. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. J Clin Oncol 2014; 32: 1050-1057.
15. Arsenic R, Lehmann A, Budczies J et al. Analysis of PIK3CA mutations in breast cancer subtypes. Diagn Mol Pathol 2014; 22: 50-56.
16. + breast cancer. Clin Cancer Res 2016 [Epub ahead of print].
17. Gianni L, Bianchini G, Kiermaier A et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC). Cancer Res 2011; 71: S5-S1.
18. Schneeweiss A, Chia S, Hegg R et al. Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. Breast Cancer Res 2014; 16: R73.
19. Baselga J, Cortés J, Kim SB et al. CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119.
20. Baselga J, Cortés J, Im SA et al. Biomarker analysis in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 2014; 32: 3753-3761.
21. Pogue-Geile KL, Song N, Jeong JH et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 2015; 33: 1340-1347.
22. Loi S, Michiels S, Lambrechts D et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 2013; 105: 960-967.
23. Untch M, von Minckwitz G, Gerber B et al. Neoadjuvant chemotherapy with trastuzumab or lapatinib: survival analysis of the HER2-positive cohort of the GeparQuinto study (GBG 44). Eur J Cancer 2015; 51: S268.
24. + advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3. J Clin Oncol 2015(Suppl): abstr 512.
25. Baselga J, Im S-A, Iwata H et al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2- advanced breast cancer (BC): first results from the randomized, Phase III BELLE-2 trial. In San Antonio Breast Cancer Symposium, 2015. Abstract S6-01.
26. Loibl S, de la Pena L, Nekljudova V et al. Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer-NeoPHOEBE. In San Antonio Breast Cancer Symposium, 2015. Abstract P1-14-01.
27. Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ et al. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. Oncotarget 2016, doi: 10.18632/oncotarget.8002 [Epub ahead of print].
28. Arsenic R, Treue D, Lehmann A et al. Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer. BMC Clin Pathol 2015; 15: 20.